Altimmune reports data from its phase 1b clinical trial of nasoshield™

Gaithersburg, md., april 01, 2021 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, reported clinical data today on its nasoshield intranasal anthrax vaccine candidate. the phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of nasoshield in healthy volunteers. the clinical trial was conducted with support from the biomedical advanced research and development authority (barda).
ALT Ratings Summary
ALT Quant Ranking